Regeneron-Sanofi's asthma drug dupilumab shows promise in trial

05/22/2013 | Reuters

Regeneron Pharmaceuticals and Sanofi's experimental injectable drug dupilumab reduced asthma attacks by 87% during a Phase IIa trial. Patients with moderate to severe asthma who took the drug also experienced improvements in symptoms and lung function. "Overall, these are the most exciting data we've seen in asthma in 20 years," said Sally Wenzel, the trial's lead investigator. The treatment could help move the care of asthma patients toward methods that address the causes of the condition rather than its symptoms, Wenzel said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ